European Car Sales Slump 23% as New Emissions Tests Start
(Bloomberg) -- Passenger car registrations in Europe slumped 23 percent during September after new emissions test rules took hold, reversing gains made in August when automakers were hurrying vehicles out the door to beat the deadline.
Key Insights
- The tougher testing methods are designed to produce results more in line with real-world conditions. Volkswagen AG will struggle to meet delivery targets this year because of the new rules. Daimler AG has also singled out so-called WLTP as an obstacle weighing on its business
- BMW, which hadn't seen delays in getting its models ready for the new regime, issued a profit warning last month partly blaming pricing pressure from less-prepared competitors
- VW on Tuesday said delays stemming from the introduction of the new test will be resolved by the fourth quarter for its namesake brand
Market Reaction
- The STOXX 600 Automobiles & Parts Index fell 1.3 percent as of 11:09 a.m. in Frankfurt
- Landesbank Baden-Wurttemberg analyst Frank Biller sees September sales as “neutral positive” for the industry
Know More
- August deliveries of new passenger cars jumped 30 percent in the European Union and European Free Trade Association from a year earlier, according to data released by the European Automobile Manufacturers Association
- In the year through September, sales are still up 2.3 percent at 12 million vehicles
- New WLTP testing procedures are applicable from Sept. 1
To contact the reporter on this story: Oliver Sachgau in Munich at osachgau@bloomberg.net
To contact the editors responsible for this story: Anthony Palazzo at apalazzo@bloomberg.net, Elisabeth Behrmann
©2018 Bloomberg L.P.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.